Is the Volume Injected a Parameter
Likely to Influence the Erectile
Response Observed after
Intracavernous Administration
of an Alpha-Blocking Agent?

Costa, P.; Sarrazin, B.; Bressolle, Françoise; Mottet, Nicholas; Jf, Louis; Saudubray, F; Navratil, H

doi:10.1159/000474260

Cited by 10 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data of 'satisfactory erection' as a common outcome measure was pooled from eight noncomparative case-series studies in the US, Australia, Italy, India, China and France (Figure 2). [23][24][25][26][27][28][29][30] Overall, these interventions resulted in a random effects pooled estimate of 90% satisfactory erection response rate (95% CI 83%, 97%). Six noncomparative case-series studies 25,26,[28][29][30][31] and one RCT 32 of 263 patients in the USA, Australia, Italy, India, China and France reported side effects ( Table 2).…”

Section: Intracavernous (Penile) Injectionsmentioning

confidence: 98%

Male erectile dysfunction following spinal cord injury: a systematic review

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Intracavernous (Penile) Injectionsmentioning

confidence: 98%

Male erectile dysfunction following spinal cord injury: a systematic review

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The drug most frequently injected was papaverine (274 men), followed by PGE1 (119 men) and the combination papaverine-phentolamine (bimix) (100 men). Moxisylyte was used in 3 different studies conducted in the same centre (29,33,34). Trimix was tested in only one study (30 men) 35).…”

Section: Studies Characteristics and Risk Of Bias Within Studiesmentioning

confidence: 99%

“…The number of patients per drug (553) differs from the number of patients in the meta-analysis of overall efficacy (713)because : i) 173 men were excluded from the meta-analysis per drug because in a few studies there was no information available regarding which drug was injected (36 4037, 39-42) and ii) 13 patients treated with two different drugs have been double-counted in the meta-analysis of the efficacy per drug (30,43). Satisfactory erection permitting sexual intercourse was obtained with papaverine (mean dosing 17 mg) in 91 % (n= 274; 95%-CI 64%;97%) (30,32,35,(43)(44)(45)(46)(47), with PGE1 (mean dosing 12 μg) in 80 % (n= 119; 95%-CI 64%;90%) (30,31,36,48,49), with bimix (mean dosing 15 mg papaverine and 0,4 mg phentolamine in 93% (n= 100; 95%-CI 83,%; 99%) (43,44,50,51), with moxisylyte (mean dosing 22 mg) in 83% (n= 30; 95%-CI 77%; 98%) (29,33,34), and with trimix (mean dosing 4 mg papaverine, 0,02 mg phentolamine, 1,5 μg PGE1) in 100 % (n= 30, 95%-CI 88%; 100%) (38). Random effects model was used in these analyses (except for moxisylyte and trimix) due to heterogeneity between the different studies (i.e.…”

Section: Subgroup Meta-analysismentioning

confidence: 99%

Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis

Chochina

Naudet

Chéhensse

et al. 2016

Sexual Medicine Reviews

View full text Add to dashboard Cite

show abstract

Comparaison randomisee en double insu d’injections intracaverneuses d’alprostadil-alfadex et de chlorhydrate de moxisylyte dans 156 cas de dysfonction erectile chronique

Buvat¹,

Amar

Cambau³

et al. 1998

Androl.

View full text Add to dashboard Cite

RESUME B u t s : C o m p a r e r l'efficacit4 et la t o l 4 r a n c e de l ' A l p r o s t a d i l -A l f a d e x et d u c h l o r h y d r a t e d e M o x i s y l y t e p o u r r i n d u c t i o n d ' 4 r e c t i o n s com-p a t i b l e s a v e c u n r a p p o r t s e x u e l d a n s le c a d r e d ' u n e 4 t u d e p r o s p e c t i v e , r a n d o m i s 4 e , e n d o u b l e i n s u , a v e c g r o u p e s p a r a l l~l e s , c h e z des s u j e t s a v e c d y s f o n c t i o n 4rectile.M 4 t h o d e : 156 sujets a v e c d y s f o n c t i o n 4recti-le d ' o r i g i n e o r g a n i q u e , n o n -o r g a n i q u e , o u m i x t e , o n t 4ta r 4 p a r t i s d e f a g o n r a n d o m i s 4 e e n 2 g r o u p e s p a r a l l~l e s c h e z l e s q u e l s la q u e le t e s t 4 t a i t p o s i t i f e n c a s d ' 6 r e c t i o n d o n t la r i g i d i t 4 a x i a l e n e se d~f o r m a i t p a s (ne p l i a i t pas)sous r e f f e t d ' u n e c h a r g e de u n k i l o g r a m m e . Le ,,buckling t e s tf u t r 4 p~t 4 t o u t e s les 10 m i n u t e s p e n d a n t j u s q u e 60 m i n u t e s lorsqu'il 6tait positif. Les sujets p u r e n t e n s u i t e f a i r e 6 a u t o -i n j e c t i o n s domicile. Les invest i g a t e u r s j u g~r e n t les 6 r e c t i o n s i n d u i t e s comp a t i b l e s a v e c u n r a p p o r t s e x u e l c h e z 61 s u j e t s d u g r o u p e A l p r o s t a d i l -A l f a d e x ( 8 1 % ) c o n t r e 37 s u j e t s d u g r o u p e c h l o r h y d r a t e d e M o x i s y l y t e (46 %). Tous les p a r a m~t r e s 4va-l u a n t r e f f i c a c i t 4 a u c a b i n e t a t t e i g n i r e n t u n e s i g n i f i c a t i o n s t a t i s t i q u e a ve c u n p < 0.001 e n f a v e u r d e l ' A l p r o s t a d i l -A l f a d e x . P e n d a n t la p h a s e d ' a u t o -i n j e c t i o n h d o m i c i l e , 58 s u j e t s d u g r o u p e A l p r o s t a d i l -A l f a d e x (85 %) r a p p o rt b r e n t a v o i r e u a u m o i n s u n e 4 r e c t i o n rigide, p a r c o m p a r a i s o n h 37 sujets d u g r o u p e chlorh y d r a t e d e M o x i s y l y t e (61%). T a n t l ' o p i n i o n d e s p a t i e n t s q u e c e l l e d e l e u r s p a r t e n a i r e s s u r l ' i n t 4 r~t d u t r a i t e m e n t a t t e i g n i r e n t d e s s c o r e s s i g n i f i c a t i v e m e n t s u p 4 r i e u r s d a n s le g r o u p e Alprostadil-Alfadex, p a r c o m p a r a i s o n a u g r o u p e c h l o r h y d r a t e d e Moxisylyte. * Liste des investigateurs ayant particip4 h l'6tude : E. Amar, L. Boccon-Gibbod, Paris ; D. Morlier, G. Arvis, Paris ; J. Buvat, A. Lemaire, Lille ; O. Cambau, A. Leriche, Saint Genis Laval ; D. Chevallier, Nice ; P. Costa, H. Navratil, Nimes ; P. Desvaux, Clichy ; J. Hermabessi~re, Clermont-Ferrand ; F. Giuliano, A. Jardin, Le Kremlin Bic~tre, P. Lansiaux, Paris ; B. Dufour, Paris ; M. Schouman, Neuilly ; A. Gout, H. Zerbib, R. Debr6, Paris * Ce texte est la version franqaise de : Double-blind multicenter study comparing Alprostadil Alfadex with moxysylyte chlor...

show abstract

Is the Volume Injected a Parameter Likely to Influence the Erectile Response Observed after Intracavernous Administration of an Alpha-Blocking Agent?

Cited by 10 publications

References 3 publications

Male erectile dysfunction following spinal cord injury: a systematic review

Male erectile dysfunction following spinal cord injury: a systematic review

Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis

Comparaison randomisee en double insu d’injections intracaverneuses d’alprostadil-alfadex et de chlorhydrate de moxisylyte dans 156 cas de dysfonction erectile chronique

Contact Info

Product

Resources

About